Skip to main content

Advertisement

Table 1 Cohort demographics

From: Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels

  Knight ADRC ADNI1 ADNI2 BIOCARD HB Mayo Sweden UPenn UW
n = 3146 805 390 397 184 105 433 293 164 375
Age (years) 70.39 ± 9.12 77.89 ± 6.89 73.28 ± 7.47 62.10 ± 9.46 67.52 ± 9.24 78.73 ± 6.35 75.15 ± 7.63 71.60 ± 8.98 62.35 ± 16
Age range (years) 37–91 58–93 55–92 23–86 45–84 50–95 50–88 50–94 21–88
Male (%) 46.09 60 54.91 41.53 54.29 60.51 37.54 41.46 50.67
APOE ε4 positive (%) 40.75 50 38.29 34.43 54.29 27.5 76.11 55.56 43.28
CDR > 0 (%) 29.34 71.28 71.03 5.43 22.17 100 62.8 33.33
42 levelsa 650.40 ± 305.59 169.83 ± 56.0 179.98 ± 51.31 386.90 ± 89.93 77.59 ± 23.30 331.0 ± 122.21 262.43 ± 72.77 163.55 ± 53.54 141.90 ± 41.42
p-tau181 levelsa 64.94 ± 34.26 34.13 ± 18.52 38.63 ± 21.21 38.94 ± 12.30 23.16 ± 10.55 105.76 ± 41.82 36.96 ± 26.80 56.56 ± 29.32
tau levelsa 372.40 ± 235.41 97.26 ± 52.03 79.69 ± 47.79 66.56 ± 26.60 84.27 ± 36.79 104.29 ± 58.06 782.20 ± 301.68 93.66 ± 54.29 61.64 ± 42.77
  1. aReported as mean ± standard deviation in pg/mL
  2. ADRC Alzheimer’s Disease Research Center, ADNI Alzheimer’s Disease Neuroimaging Initiative, APOE apolipoprotein E, BIOCARD Predictors of Cognitive Decline Among Normal Individuals, CDR Clinical Dementia Rating, HB Saarland University in Homburg/Saar, Germany, Mayo Mayo Clinic, Sweden Sahlgren’s University Hospital, Sweden, UPenn Perelman School of Medicine at the University of Pennsylvania, UW University of Washington